Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

BUY
$56.44 - $118.81 $220,793 - $464,784
3,912 New
3,912 $235,000
Q3 2022

Oct 14, 2022

SELL
$67.99 - $89.57 $2,039 - $2,687
-30 Reduced 0.68%
4,373 $332,000
Q2 2022

Jul 13, 2022

SELL
$56.6 - $89.9 $20,489 - $32,543
-362 Reduced 7.6%
4,403 $306,000
Q1 2022

May 12, 2022

SELL
$60.15 - $84.52 $56,661 - $79,617
-942 Reduced 16.51%
4,765 $395,000
Q4 2021

Feb 10, 2022

SELL
$75.08 - $121.99 $35,587 - $57,823
-474 Reduced 7.67%
5,707 $428,000
Q3 2021

Oct 14, 2021

BUY
$116.17 - $194.55 $48,442 - $81,127
417 Added 7.23%
6,181 $718,000
Q2 2021

Aug 12, 2021

SELL
$130.4 - $225.58 $86,455 - $149,559
-663 Reduced 10.32%
5,764 $1.28 Million
Q1 2021

Apr 22, 2021

SELL
$124.11 - $190.17 $39,715 - $60,854
-320 Reduced 4.74%
6,427 $850,000
Q4 2020

Apr 01, 2021

SELL
$112.16 - $174.14 $29,722 - $46,147
-265 Reduced 3.78%
6,747 $1.17 Million
Q3 2020

Nov 02, 2020

BUY
$58.05 - $111.31 $3,192 - $6,122
55 Added 0.79%
7,012 $781,000
Q2 2020

Aug 17, 2020

SELL
$57.2 - $74.41 $5,605 - $7,292
-98 Reduced 1.39%
6,957 $413,000
Q1 2020

May 12, 2020

BUY
$57.05 - $95.75 $86,145 - $144,582
1,510 Added 27.23%
7,055 $475,000
Q4 2019

Feb 10, 2020

BUY
$68.3 - $93.8 $39,955 - $54,873
585 Added 11.79%
5,545 $467,000
Q3 2019

Nov 13, 2019

SELL
$61.86 - $97.8 $20,723 - $32,763
-335 Reduced 6.33%
4,960 $371,000
Q2 2019

Aug 14, 2019

SELL
$42.22 - $63.23 $30,820 - $46,157
-730 Reduced 12.12%
5,295 $335,000
Q1 2019

May 13, 2019

SELL
$31.96 - $56.12 $5,593 - $9,821
-175 Reduced 2.82%
6,025 $290,000
Q4 2018

Feb 11, 2019

BUY
$28.72 - $52.63 $4,738 - $8,683
165 Added 2.73%
6,200 $208,000
Q3 2018

Nov 01, 2018

BUY
$32.0 - $52.4 $193,120 - $316,234
6,035 New
6,035 $316,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.48B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.